Delivery Order SPE2DB22D9143-SPE2DB24FZC23

Award Date 6/17/24
Potential Completion Date 6/18/24
Potential Value $19K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a $18,526.83 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. This order for the drug Trikafta is being fulfilled under a larger single-award indefinite delivery contract (IDC), valued up to $499,999,999, awarded to DMS by the DLA. The IDC, which runs through December 31, 2025, allows the DLA to issue delivery orders for a comprehensive range of...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $18,526.83 firm fixed-price contract is for the supply of Trikafta, a prescription medication used to treat cystic fibrosis. This delivery order is part of a larger $499,999,999 indefinite delivery contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program. This single-award...
The U.S. government's Defense Logistics Agency (DLA) awarded a delivery order contract valued at $18,526.83 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, which has a fixed-price pricing type and a completion date of May 16, 2024, is for the delivery of various pharmaceutical products, including Trikafta, a treatment for cystic fibrosis. This contract is part of a larger indefinite delivery contract (IDC)...
This delivery order, valued at $37,053.68, was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The order is for the delivery of Trikafta, a specialty pharmaceutical product, and is issued under DMS Pharmaceutical Group's $499,999,999 Indefinite Delivery Contract (IDC) with the DLA. The IDC, valid through November 2026, enables the DLA to issue firm fixed-price delivery orders for...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $18,318.75 firm fixed-price contract is for the delivery of Trikafta, a medication used to treat cystic fibrosis. The award is issued under a larger $499,999,999 indefinite delivery contract (IDC) held by DMS Pharmaceutical Group with the DLA, which allows the agency to issue delivery orders for a...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $36,637.50 contract is for the delivery of the specialized pharmaceutical product Trikafta, a medication used to treat cystic fibrosis. The delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $18,526.83, is to provide the pharmaceutical product Trikafta, a specialty medication used to treat cystic fibrosis. The order has an ultimate completion date of November 20, 2024. DMS Pharmaceutical Group is a key supplier in the DLA's pharmaceutical supply chain,...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The order, valued at $18,526.83, is for the provision of Trikafta, a cystic fibrosis medication, with a period of performance through May 23, 2024. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which runs through December 31, 2025....
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $37,053.68, is for the delivery of Trikafta 100-50-75 mg/150 mg oral pharmaceutical medication. The contract is a firm fixed-price delivery order placed under a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group that has a ceiling value of up to...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $18,526.83, is for the delivery of Trikafta, a specialized pharmaceutical product, with a completion date of November 7, 2024. This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) between DMS Pharmaceutical Group and the DLA under...
  • SPE2DB22D9143
    Indefinite Delivery Contract
  • SPE2DB22D9143-SPE2DB24FZC23
    Delivery Order

This is a delivery order awarded by the Defense Logistics Agency (DLA) on June 17, 2024 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $18,526.83 firm fixed-price contract provides the DLA with Trikafta, a prescription medication used to treat cystic fibrosis. This order is part of a larger $499,999,999 indefinite delivery contract (IDC) held by DMS Pharmaceutical Group that allows the DLA to issue delivery orders for a wide range of pharmaceutical products to support the medical supply needs of military health facilities worldwide. The contract has no set-aside designation.

Generated 9/16/24, 10:29 AM